Funder
Novartis Pharma
Otsuka Pharmaceutical
Novartis Pharmaceuticals Corporation
Japan Heart Foundation
Subject
Cardiology and Cardiovascular Medicine
Reference36 articles.
1. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2022;24:4-131. doi: https://10.1002/ejhf.2333
2. 9-year trend in the management of acute heart failure in Japan: A report from the National Consortium of Acute Heart Failure Registries;Shiraishi;J Am Heart Assoc,2018
3. JCS 2017/JHFS 2017 Guideline on diagnosis and treatment of acute and chronic heart failure - Digest Version;Tsutsui;Circ J,2019
4. Heart failure a cluster of comorbidities or a unique entity?;Oikonomou;Int J Cardiol,2019
5. Efficacy and safety of dapagliflozin according to frailty in heart failure with reduced ejection fraction: A post hoc analysis of the DAPA-HF Trial;Butt;Ann Intern Med,2022
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Yes, frailty matters. Time for action.;Canadian Journal of Cardiology;2024-01